Drägerwerk AG & Co. KGaA
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DWRKF research report →
Price Chart
About the company
Headquartered in Lübeck, Germany, and established in 1889, Drägerwerk AG & Co. KGaA is an international enterprise specializing in medical and safety technology, with operations spanning Europe, the Americas, Africa, Asia, and Australia. For the healthcare sector, the company engineers, produces, and commercializes comprehensive solutions, apparatus, and related services tailored for acute care environments, such as emergency, perioperative, critical, and perinatal settings.
- CEO
- Stefan A. Drager
- IPO
- 2017
- Employees
- 15,170
- HQ
- Lübeck, DE
Get TickerSpark's AI analysis on DWRKF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.75B
- P/E
- 13.16
- PEG
- 0.33
- P/S
- 0.55
- P/B
- 1.31
- EV/EBITDA
- 4.79
- Div Yield
- 1.91%
- Gross Margin
- 46.39%
- Op Margin
- 7.40%
- Net Margin
- 4.72%
- ROE
- 10.20%
- ROIC
- 7.59%
- 52W High
- $543.70
- 52W Low
- $543.70
- 50D MA
- $543.70
- 200D MA
- $543.70
- Beta
- -0.19
- RSI (14)
- 100
- Avg Volume
- 0
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Drägerwerk delivered strong 9M 2026 sales, profit and cash flow growth, supported by customs refunds and healthy demand, while reaffirming full-year guidance.· October 29, 2026
- Order intake rose 3.6% in 9M to around EUR 2.7 billion; net sales rose 5.3% to around EUR 2.5 billion.
- EBIT increased to around EUR 112 million, lifting the EBIT margin to 4.6%; management said customs refunds were the main driver, though underlying improvement still remained.
- Free cash flow jumped to around EUR 114 million from around EUR 16 million a year earlier, helped by better working capital management.
- Full-year guidance was confirmed: 2% to 6% currency-adjusted sales growth and an EBIT margin of 6% to 8%.
- Medical was mixed, with 9M order intake down 3.5% and Q3 sales down 1.4%, while Safety posted strong double-digit order growth and higher profitability.
Drägerwerk reported 9M 2026 order intake of around EUR 2.7 billion, net sales of around EUR 2.5 billion, EBIT of around EUR 112 million, and an EBIT margin of 4.6%. Management said net sales increased by around EUR 110 million and earnings rose by roughly EUR 35 million versus the prior year period, while free cash flow increased to around EUR 114 million from around EUR 16 million. Gross margin rose to 46.8%, up 1.7 percentage points, helped by customs refunds; net tariff impact year-to-date was still negative by roughly EUR 2 million. For the full year 2026, the company confirmed guidance for currency-adjusted sales growth of 2% to 6% and an EBIT margin of 6% to 8%.
Stefan Dräger described 2026 as “very successful” so far and emphasized continued good demand, strong top-line growth and a lift in profitability and cash generation. He said the company sees no unusual product- or region-specific issue in order development, expects Q4 to be the strongest quarter, and pointed to upcoming strategic updates at the November 18 Capital Markets Day. He also framed defense, the lifted FDA warning letter, and select large opportunities such as FDNY as future upside, while saying China remains below expectations.
Gert-Hartwig Lescow highlighted that 9M order intake rose 3.6%, sales rose 5.3%, gross margin improved to 46.8%, and EBIT increased to around EUR 112 million. He noted functional expenses were up 6.1% in 9M and 8.7% in Q3 because of personnel, logistics, IT, collective bargaining costs, variable management compensation accruals, freight, and a leased distribution center transition in Lübeck. He also said operating cash flow rose by around EUR 82 million to around EUR 175 million, free cash flow improved by around EUR 98 million, net financial debt fell by around EUR 116 million to around EUR 106 million, and net debt/EBITDA improved to 0.3; equity ratio was about 52%.
Analysts focused on Medical margin improvement, the flat-ish Medical order trend after stripping out the Mexico effect, and whether functional costs can stay below sales growth in Q4. Management said Medical improvement is being driven by sales growth, better monitoring portfolio positioning after the warning letter, and higher R&D efficiency, but avoided detailed margin-roadmap disclosure until the Capital Markets Day. On costs, management confirmed Q4 will require tighter spending control, and said about one-third of the Q3 increase reflected one-offs that should not repeat. Questions also probed the defense order in Germany, where management said the current order was a low double-digit million, multi-year contract, and the FDA warning letter, which management said is now lifted after almost 7 years, with further implications to be outlined later.
The call showed solid demand trends overall, with strong Safety momentum, higher sales, and meaningful cash generation. Management sounded optimistic about defense, post-FDA opportunities, and select large contracts, while confirming full-year guidance and saying Q4 should be the best quarter.
Medical remains softer, with 9M order intake down 3.5% and China still below expectations, and management did not point to a near-term turnaround there. Cost pressure also remains a risk: functional expenses rose faster than sales in the first nine months, and management acknowledged Q4 will require tight spending control to meet the full-year target.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 0.0%
- Shares Outstanding
- 3.22M
- Float Shares
- 0
Our DWRKF coverage
Recent articles, reports, and earnings notes.
No research on DWRKF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DWRKF report →